WELCOMING DANIEL SU, MD

Dr. Daniel Su graduated Magna cum Laude from UCLA with a Bachelor’s degree in Electrical Engineering. He received his Doctor of Medicine degree from the Icahn School of Medicine at Mount Sinai in New York, where he was elected to the Alpha Omega Alpha Medical Honor Society and graduated with Distinction in Research.

Following an internship at Cedars-Sinai Medical Center in Los Angeles, he completed his residency training in ophthalmology at the Jules Stein Eye Institute at UCLA, where he was recognized both with the Jules Stein Resident Awards for Surgical Excellence and Clinical Research. He went on to complete a two-year vitreoretinal surgical fellowship at the renowned Wills Eye Hospital in Philadelphia, during which time he was awarded the prestigious national award from the Heed Ophthalmic Foundation.

Dr. Su has authored numerous peer-reviewed scientific publications and textbook chapters on vitreoretinal diseases and has been an invited speaker to present scientific papers and abstracts at various national ophthalmic and retina subspecialty meetings. Dr. Su is fluent in Mandarin Chinese.

INAUGURAL USC-RVA JOINT VITREORETINAL FELLOWSHIP

We are excited and proud to announce that we have joined forces with the USC Roski Eye Institute to form a joint Vitreoretinal Surgical Fellowship training program. We have created a true hybrid training program, allowing fellows-in-training to experience the full gamut of vitreoretinal practice: academics, LA County Medical Center (LAC+USC), and retina-only private practice. We look to bring one of the top training programs in the country to even greater heights!

NEW GLENDALE OFFICE!

To better meet the needs of our patients and extensive referral doctor network, we have now opened a Glendale office location!

1510 S. Central Ave., Suite 230
Glendale, CA 91204
Phone # (818) 797-4870    Fax # (818) 797-4970

SAVE THE DATE: ANNUAL RETINA UPDATE CONFERENCE – SUNDAY, MARCH 15, 2020

www.LAretina.com
CURRENTLY ENROLLING CLINICAL TRIALS

Retina-Vitreous Associates Medical Group has participated in clinical research for over 15 years and is committed to the development of novel diagnostic and therapeutic modalities for retinal disease. All of our physicians participate in clinical trials, giving patients unique and easy access to the latest developments in treatments of vitreoretinal diseases. We are committed to bettering the quality, efficacy, and ease of treatment for our patients. Transportation may be provided.

RETINITIS PIGMENTOSA (RP)
A genetic condition causing progressive vision loss. Night blindness usually occurs first, followed by peripheral, central, and color vision loss.
We offer injections of human stem cell-derived retinal progenitor cells in the office that may offer long-term visual benefits to patients who otherwise have no other treatments available.

MACULAR DEGENERATION (Age-related/AMD)
The leading cause of vision loss in America, AMD is progressive disorder affecting the central vision in patients 50 years or older.
“Dry” macular degeneration: currently no treatment available.
“Wet” macular degeneration: current standard of care treatment includes frequent eye injections
We provide trials for both early and end stage dry and wet AMD using in-office as well as surgical treatments.

DIABETIC RETINOPATHY
Patients with type 1 and type 2 diabetes can suffer from damage to the blood vessels in the retina, causing mild to severe vision loss and potentially blindness.
Currently under investigation are an orally administered pill and a subcutaneous (underneath the skin) self-administered injection.

DIABETIC MACULAR EDEMA (DME)
An accumulation of swelling in the central retina that causes vision loss in diabetic patients. This is a component of diabetic retinopathy.
Our trials look for novel treatments for diabetic macular edema and in combination with current gold-standard treatment.

RETINAL VEIN OCCLUSION (CRVO and BRVO)
Commonly referred to as a “stroke in the eye”, a blood clot in the retinal blood vessels can cause vision loss and secondary glaucoma.
We are investigating multiple novel treatments to improve outcomes and decrease the number of necessary visits and procedures.

UVEITIS: ANTERIOR, INTERMEDIATE, POSTERIOR, AND PAN-UVEITIS
A broad term for inflammation of the eye, it can be classified based on the parts of the eye that are affected.
We offer a spectrum of treatments including eye drops, subcutaneous injections, and oral medication for various types of uveitis.

STARGARDT DISEASE NEW!
A rare genetic macular condition (ABCA4 mutation) for which we are now offering a Phase 3 treatment trial.

MACULAR TELANGIECTASIA/IDIOPATHIC JUXTAFOVEAL RETINAL TELANGIECTASIS NEW!
Another rare bilateral macular disease of unknown cause that usually causes mild to moderate vision loss.
RVA 2019 PUBLICATIONS


“This is hands down a world class retina hub! …I was super nervous about everything but walked out feeling much calmer than when I went in. On top of the incredible care they provide for their patients, they also have a nonprofit foundation … as well as conducting research to help find treatments for incurable retinal diseases. Big thumbs up and thank you so much for what you do!”
- Tony D., Victorville, CA

"Best possible experience! … He was incredibly knowledgeable and had a wonderful bedside manner. Long story short he was able to give me a 99% sure diagnoses and calmed me down… I could not have had a better experience and would highly recommend them to everyone. Thank you RVA Group! "
- Kimberly S., Los Angeles, CA

We are committed to providing our clients with a positive experience, your feedback helps make that possible. Thank you!